SG11202003225YA - Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof - Google Patents
Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereofInfo
- Publication number
- SG11202003225YA SG11202003225YA SG11202003225YA SG11202003225YA SG11202003225YA SG 11202003225Y A SG11202003225Y A SG 11202003225YA SG 11202003225Y A SG11202003225Y A SG 11202003225YA SG 11202003225Y A SG11202003225Y A SG 11202003225YA SG 11202003225Y A SG11202003225Y A SG 11202003225YA
- Authority
- SG
- Singapore
- Prior art keywords
- amine
- synthesis
- salts
- methods
- substituted heterocyclic
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573917P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/056428 WO2019079540A1 (en) | 2017-10-18 | 2018-10-18 | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003225YA true SG11202003225YA (en) | 2020-05-28 |
Family
ID=66173899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003225YA SG11202003225YA (en) | 2017-10-18 | 2018-10-18 | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200247790A1 (enExample) |
| EP (1) | EP3697762A4 (enExample) |
| JP (2) | JP2021500334A (enExample) |
| KR (1) | KR20200101330A (enExample) |
| CN (1) | CN111417628A (enExample) |
| AU (2) | AU2018353122B2 (enExample) |
| BR (1) | BR112020007632A2 (enExample) |
| CA (1) | CA3079273A1 (enExample) |
| CL (1) | CL2020001009A1 (enExample) |
| CO (1) | CO2020005944A2 (enExample) |
| EA (1) | EA202090959A1 (enExample) |
| IL (2) | IL301746B2 (enExample) |
| MA (1) | MA50418A (enExample) |
| MX (2) | MX2020007152A (enExample) |
| SG (1) | SG11202003225YA (enExample) |
| WO (1) | WO2019079540A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018221705B2 (en) | 2017-02-17 | 2022-10-27 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| MX2020003862A (es) | 2017-10-18 | 2020-08-13 | Incyte Corp | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
| JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
| WO2025240956A1 (en) * | 2024-05-17 | 2025-11-20 | Yale University | G9a/ehmt2 inhibitor use for prader-willi syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| MY167260A (en) * | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| JP6527534B2 (ja) * | 2014-06-16 | 2019-06-05 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 |
| CA2952474A1 (en) * | 2014-06-23 | 2015-12-30 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| EP3442947B1 (en) * | 2016-04-15 | 2023-06-07 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| EP3555070B1 (en) * | 2016-12-19 | 2023-08-09 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| CA3079412A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
-
2018
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en not_active Ceased
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en not_active Withdrawn
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111417628A (zh) | 2020-07-14 |
| CA3079273A1 (en) | 2019-04-25 |
| EA202090959A1 (ru) | 2020-07-13 |
| IL301746B2 (en) | 2025-01-01 |
| IL273974B2 (en) | 2023-08-01 |
| AU2018353122A1 (en) | 2020-06-04 |
| MA50418A (fr) | 2021-04-07 |
| JP2023036991A (ja) | 2023-03-14 |
| IL273974A (en) | 2020-05-31 |
| CO2020005944A2 (es) | 2020-07-31 |
| IL301746B1 (en) | 2024-09-01 |
| AU2018353122B2 (en) | 2023-11-23 |
| AU2024201165A1 (en) | 2024-03-14 |
| CL2020001009A1 (es) | 2020-12-18 |
| IL301746A (en) | 2023-05-01 |
| US20220324851A1 (en) | 2022-10-13 |
| EP3697762A1 (en) | 2020-08-26 |
| BR112020007632A2 (pt) | 2020-09-29 |
| WO2019079540A1 (en) | 2019-04-25 |
| MX2024012124A (es) | 2025-02-10 |
| IL273974B1 (en) | 2023-04-01 |
| JP2021500334A (ja) | 2021-01-07 |
| KR20200101330A (ko) | 2020-08-27 |
| MX2020007152A (es) | 2020-12-10 |
| EP3697762A4 (en) | 2021-04-07 |
| US20200247790A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267090A (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them | |
| IL281319A (en) | Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors | |
| IL273428A (en) | Heterocyclic compounds as PAD inhibitors | |
| ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
| IL273974B1 (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors, salts thereof and method for their synthesis | |
| ZA201704382B (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
| PL3059227T3 (pl) | Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3 | |
| IL254430A0 (en) | Heterocyclic compounds are useful as TNF inhibitors | |
| HK40036207A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof | |
| HK40091939A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 | |
| HK40033780A (en) | Heterocyclic compounds as pad inhibitors | |
| HK40012933A (en) | Heterocyclic compounds as inhibitors of ras and methods of use thereof |